Related Experiment Video
Updated: Jul 12, 2025

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry
Published on: April 21, 2022
The role of m6A RNA methylation regulator in meningioma
Yu Yang1,2, Liqin Luo2,3, Zhiwu Zhou2,4
1Department of Neurosurgery, Jiangxi Provincial People’s Hospital, Nanchang 330006, Jiangxi, China.
Abstract:
Meningiomas are common intracranial tumors, and the effect of surgical resection is often unsatisfactory. N6-Methyladenosine (m6A)-related regulator expression levels are related to cancer occurrence and development. This study aimed to investigate the roles of m6A RNA methylation regulators in meningiomas, as these are currently unclear. Two m6A methylation-regulated genes (METTL3 and IGF2BP2) were identified as survival-associated linear models for RiskScore through bioinformatics analysis. Univariate and multivariate Cox regression analyses showed that the overall survival of patients with meningioma in the high-risk group was substantially shorter than that in the low-risk group. Weighted gene co-expression network analysis constructed a co-expression network based on the m6A methylation model (RiskScore). Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes analyses identified the biological processes of hub module gene behavior, and Cytoscape constructed an m6A methylation-related gene regulatory network. In vitro experiments verified that the mRNA and protein expression levels of METTL3 and IGF2BP2 were lower in meningioma cells than in normal meningioma cells. Therefore, central regulators of m6A methylation (METTL3 and IGF2BP2) could potentially serve as novel therapeutic targets in meningioma. Subsequently, a novel methylation signature (RiskScore) was developed for prognostic prediction in patients with meningioma.
Insights
N6-Methyladenosine (m6A) regulators METTL3 and IGF2BP2 are crucial in meningioma development. Lower expression of these m6A regulators indicates poorer survival, suggesting they are potential therapeutic targets for meningioma.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Meningiomas are common intracranial tumors with often unsatisfactory surgical outcomes.
- N6-Methyladenosine (m6A) RNA methylation regulators are implicated in various cancers.
- The specific roles of m6A regulators in meningioma pathogenesis remain largely unelucidated.
Purpose of the Study:
- To investigate the involvement of m6A RNA methylation regulators in meningioma.
- To identify potential prognostic biomarkers and therapeutic targets for meningioma.
Main Methods:
- Bioinformatic analysis including Cox regression and weighted gene co-expression network analysis.
- Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses.
- In vitro experiments to validate gene expression levels in meningioma cells.
Main Results:
- METTL3 and IGF2BP2 were identified as key m6A regulators associated with patient survival.
- A novel methylation signature (RiskScore) was developed for prognostic prediction.
- Lower mRNA and protein expression of METTL3 and IGF2BP2 were observed in meningioma cells compared to normal cells.
Conclusions:
- METTL3 and IGF2BP2 play significant roles in meningioma and could serve as novel therapeutic targets.
- The developed RiskScore methylation signature shows potential for prognostic prediction in meningioma patients.
Related Concept Videos
Epigenetic Regulation
Master Transcription Regulators
MicroRNAs
Abnormal Proliferation
RNA Stability
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...

